Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer [Accessibility Statement] Skip NavigationVeteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive teamSECAUCUS, N.J., Feb. 26, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and t ...

Secaucus, New Jersey-based Quest Diagnostics Incorporated (DGX) provides diagnostic testing and services in the United States and internationally. Valued at a market capitalization of $23 billion, the company develops and delivers diagnostic information services, including routine, non-routine, and advanced clinical testing, anatomic pathology testing, and other diagnostic services. The company's shares have outperformed the broader market over the past year and in 2026. DGX stock has surged 21.8% over t ...

Core Insights - Quest Diagnostics reported strong financial results for Q4 and full year 2025, with double-digit growth in revenues and earnings per share, reflecting effective execution of its strategic initiatives [1] - The company provided guidance for full year 2026, projecting reported diluted EPS between $9.45 and $9.65, and adjusted diluted EPS between $10.50 and $10.70, alongside expected revenues of $11.70 billion to $11.82 billion [1][2] Financial Performance - Full year 2025 reported diluted EPS was $8.75, up 13.8% from 2024, with adjusted diluted EPS at $9.85, up 10.3% from 2024 [1] - Full year revenues reached $11.04 billion, an increase of 11.8% from 2024, while Q4 revenues were $2.81 billion, up 7.1% from the previous year [1] - Operating income for 2025 was $1.56 billion, a 15.6% increase from 2024, with net income attributable to Quest Diagnostics at $992 million, up 13.9% from 2024 [1][2] Strategic Initiatives - The company formed a collaboration with Epic for Project Nova, aimed at improving customer experiences and streamlining systems [1] - Quest Diagnostics expanded its service offerings, integrating eight acquisitions from 2024 and scaling lab testing for over 200,000 patients at Fresenius Medical Care's dialysis centers [1] - New clinical innovations were introduced, including the Haystack MRD® test for cancer monitoring and the Quest AD-Detect® blood test for Alzheimer's diagnosis [1] Operational Excellence - The company engaged Google Cloud to enhance data management and analytics through generative AI, and deployed AI and automation across various systems to improve productivity [1] - Quest Diagnostics achieved 3% annual cost savings and productivity improvements through its Invigorate program [1] Shareholder Returns - The company announced a 7.5% increase in its quarterly dividend to $0.86 per share, marking 15 consecutive years of dividend increases [5] - A $1 billion increase in share repurchase authorization was also announced, reflecting the company's commitment to returning value to shareholders [5]

Core Viewpoint - Quest Diagnostics has announced a 7.5% increase in its quarterly cash dividend to $0.86 per share, effective April 20, 2026, with an annual cash dividend totaling $3.44 per share [1] Group 1: Dividend Increase - The Board of Directors has authorized a 7.5% increase in the quarterly cash dividend from $0.80 to $0.86 per share [1] - The increase will be effective for the dividend payable on April 20, 2026, to shareholders of record on April 6, 2026 [1] - The annual cash dividend will now amount to $3.44 per share [1] Group 2: Share Repurchase Authorization - The Board of Directors has increased the Company's share repurchase authorization by $1 billion [2] - This increase is in addition to the approximately $0.4 billion that was available as of December 31, 2025, under the share repurchase program [2] Group 3: Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, connecting clinicians and consumers with laboratory insights [3] - The company serves half of the physicians and hospitals in the United States and one in three American adults each year [3] - Quest Diagnostics employs nearly 57,000 individuals to deliver diagnostic insights that inspire actions to improve health [3]

Core Insights - Quest Diagnostics has launched a novel blood test called Quest Flow Cytometry MRD for Myeloma, which offers sensitivity comparable to next-generation sequencing (NGS) methods for detecting measurable residual disease (MRD) in myeloma patients at a lower cost [1][4]. Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, with a focus on oncology testing, including the new MRD test for myeloma and the Haystack MRD® test for solid tumors [6][8]. - The company operates approximately 7,000 phlebotomy sites across the United States, enhancing patient access to diagnostic testing [2]. Industry Context - Myeloma is a prevalent blood cancer with about 36,000 new cases diagnosed annually in the U.S., leading to nearly 11,000 deaths each year [3]. - The new test utilizes advanced flow cytometry techniques, providing a noninvasive alternative to traditional bone marrow aspirates, which is significant for patient care [4]. Test Features and Benefits - The Quest Flow Cytometry MRD for Myeloma test features five-day specimen stability, allowing for better logistics in specimen transport compared to conventional methods [4]. - The test is designed to be used even when a baseline aspirate sample is unavailable, unlike NGS methods that require such a reference [4]. Clinical Implications - The test is expected to improve treatment paradigms for myeloma patients and may serve as a response monitoring tool in clinical trials, aligning with recent FDA guidance on using MRD as a primary endpoint [5].

IDEXX Q4 & Full Year 2025 Earnings Highlights (NASDAQ: IDXX) | Revenue | | | | Operating | | Diluted | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | Profit | | | Earnings Per Share | | | | | Q4 | $1,091M | | | $316M | | $3.08 | | | | | Reported growth: | | +14% | 29% | of Revenue | | | | | | | Organic growth: | | +12% | | | | Reported growth: | | | +18% | | | | | YoY change in basis points: | | | | | | | | CAG Diagnostics Recurring | | | Reported | | +150 | Comparable growth: | ...

Upgrades - BMO Capital upgraded Southwest (LUV) to Outperform from Market Perform with a price target of $57.50, up from $43, citing significant momentum and earnings upside to at least $4.00 per share in 2026 from 93 cents in 2025 [2] - Barclays upgraded Quest Diagnostics (DGX) to Overweight from Equal Weight with a price target of $210, up from $195, noting sustainable organic growth of 4% from fiscal 2024 to 2025 [3] - Guggenheim upgraded GE Vernova (GEV) to Buy from Neutral with a price target of $910, believing the market may underestimate cash generation potential and margin improvement in the electrification segment [4] - Wolfe Research upgraded Broadcom (AVGO) to Outperform from Peer Perform with a price target of $400, based on channel checks indicating the company will ship 7 million tensor processing units by 2028 [5] - Citi upgraded Spotify (SPOT) to Buy from Neutral with an unchanged price target of $650, stating the stock's valuation is now attractive and consensus estimates are beatable [5] Downgrades - HSBC downgraded Pinterest (PINS) to Hold from Buy with a price target of $24.90, down from $34.50, due to an abrupt jobs cut announcement indicating a softer near-term outlook [6] - Jefferies downgraded Kenvue (KVUE) to Hold from Buy with a price target of $18, down from $23, following shareholder approval for a merger with Kimberly-Clark [6] - Citizens downgraded SAP (SAP) to Market Perform from Outperform without a price target, citing disappointing Q4 sales results and a current cloud backlog growth of 25% versus the expected 26% [6] - D. Boral Capital downgraded Quince Therapeutics (QNCX) to Hold from Buy without a price target after negative results from a pivotal Phase 3 clinical trial [6] - Stifel downgraded Codere Online (CDRO) to Hold from Buy with a price target of $8.50, down from $9, believing the company's estimates need to reset due to a recently announced tax hike in Mexico [6]

Core Viewpoint - NeoGenomics, Inc. will report its fourth quarter and full year 2025 financial results on February 17, 2026, prior to the U.S. market opening, with a subsequent webcast and conference call scheduled for discussion [1]. Company Overview - NeoGenomics, Inc. is a leading cancer diagnostics company that specializes in cancer genetics testing and information services, providing a comprehensive oncology-focused testing menu [3]. - The company serves a variety of clients including oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms, offering innovative diagnostic and predictive testing to aid in cancer diagnosis and treatment [3]. - Headquartered in Fort Myers, Florida, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories across the U.S. and a CAP-accredited laboratory in Cambridge, United Kingdom [3].

Core Viewpoint - NeoGenomics is transitioning from a commodity diagnostic service provider to a comprehensive precision oncology platform, indicating a strategic shift in its business model to enhance its market position and service offerings [1]. Company Strategy - The company is focusing on leveraging first mover advantages in the minimal residual disease (MRD) monitoring sector, which is gaining significant attention in the oncology market [1]. Market Position - The shift towards a precision oncology platform suggests that NeoGenomics aims to differentiate itself from competitors by offering more specialized and advanced diagnostic services [1].

Group 1 - Guardant Health, Inc. (GH) is expected to benefit from a collaboration with Quest Diagnostics (DGX), which will enhance access to Shield colorectal cancer screening [1] - The collaboration provides Guardant access to over 650,000 patients, potentially increasing its market reach and revenue opportunities [1] Group 2 - The analyst emphasizes a unique investment approach called "First Principles," which focuses on breaking down complex problems to identify overlooked investment opportunities [1] - The analyst has a strong background in investment, private equity, and venture capital, with a proven track record of delivering strong returns [1]